NDC 16729-367-45 - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 16729-367
- Requested NDC
- 16729-367-45
- Package NDCs from labels
- 16729-367-10, 16729-367-15, 16729-367-16, 16729-367-17, 16729-367-45, 16729-367-46
- Manufacturer
- Accord Healthcare Inc. | Intas Pharmaceuticals Limited
- Effective date
- 2025-10-29
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| LACTOSE MONOHYDRATE - Accord Healthcare Inc. | Intas Pharmaceuticals Limited | Accord Healthcare Inc. | Intas Pharmaceuticals Limited | 2025-10-29 | HUMAN PRESCRIPTION DRUG LABEL |
| OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE - A-S Medication Solutions | A-S Medication Solutions | 2024-11-13 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 16729-367-10 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 30 in 1 BOTTLE | TABLET, FILM COATED | 30 | 7 | |
| 16729-367-15 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 90 in 1 BOTTLE | TABLET, FILM COATED | 90 | 7 | |
| 16729-367-16 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 500 in 1 BOTTLE | TABLET, FILM COATED | 500 | 7 | |
| 16729-367-17 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 1000 in 1 BOTTLE | TABLET, FILM COATED | 1000 | 7 | |
| 16729-367-45 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 10 in 1 BLISTER PACK | TABLET, FILM COATED | 10 | 7 | |
| 16729-367-46 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 100 in 1 CARTON | TABLET, FILM COATED | 100 | 7 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 16729-367-10 | EA - Each | 16729-367 | aea7451f-249f-4002-a7df-f367e3bb0513 | 1 | 2020-09-14 |
| 16729-367-15 | EA - Each | 16729-367 | 0eff996a-5135-4a4b-a09e-70ccc66334d4 | 1 | 2020-09-14 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Dolce and Gabbana Everlast Foundation SPF 20 03W Light | OCTISALATE, OCTOCRYLENE, TITANIUM DIOXIDE, ZINC OXIDE | Dolce & Gabbana Beauty S.R.L | 3b1e4480-8409-425e-b98d-eb4dcf2471e8 | 2025-08-04 | Warnings | 15FIX9V2JP |
| Dolce and Gabbana Everlast Foundation SPF 20 06W Light | OCTISALATE, OCTOCRYLENE, TITANIUM DIOXIDE, ZINC OXIDE | Dolce & Gabbana Beauty S.R.L | 3090422e-fc18-45b8-88f2-6a9b282a7205 | 2025-08-04 | Warnings | 15FIX9V2JP |
| Dolce and Gabbana Everlast Foundation SPF 20 05N Light | OCTISALATE, OCTOCRYLENE, TITANIUM DIOXIDE, ZINC OXIDE | Dolce & Gabbana Beauty S.R.L | f93aa5d2-90ab-4e11-874e-2ede4b25c4b6 | 2025-08-04 | Warnings | 15FIX9V2JP |
| Dolce and Gabbana Everlast Foundation SPF 20 04C Light | OCTISALATE, OCTOCRYLENE, TITANIUM DIOXIDE, ZINC OXIDE | Dolce & Gabbana Beauty S.R.L | f055cd51-7b1d-43df-8990-8f60ba1eb91c | 2025-08-04 | Warnings | 15FIX9V2JP |
| Dolce and Gabbana Everlast Foundation SPF 20 07N Light | OCTISALATE, OCTOCRYLENE, TITANIUM DIOXIDE, ZINC OXIDE | Dolce & Gabbana Beauty S.R.L | d4c76bc5-205b-45fd-8a02-4f4b17458503 | 2025-08-04 | Warnings | 15FIX9V2JP |
| Olmesartan medoxomil Amlodipine and Hydrochlorothiazide | OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE | Macleods Pharmaceuticals Limited | 52c013e1-8c31-4bed-9241-e7845873ebe8 | 2025-08-04 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH 6M97XTV3HD |
| Losartan Potassium and Hydrochlorothiazide | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | Preferred Pharmaceuticals Inc. | 46cf633d-70a5-4d3b-b349-ad74c23ddace | 2025-08-04 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Losartan Potassium and Hydrochlorothiazide | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | Preferred Pharmaceuticals Inc. | 24ee299f-4466-45d4-9013-17791e1998bb | 2025-08-04 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| VALSARTAN AND HYDROCHLOROTHIAZIDE | VALSARTAN AND HYDROCHLOROTHIAZIDE | Solco Healthcare US, LLC | f8b0a8ab-4549-4553-a127-bf2c0291a4b1 | 2025-07-31 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Triamterene and Hydrochlorothiazide | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | NuCare Pharmaceuticals, Inc. | 3b3c92b1-bec3-2768-e063-6394a90a9af8 | 2025-07-31 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Neutrogena Mineral Invisible Daily Defense Face Sunscreen Broad Spectrum SPF 30 | TITANIUM DIOXIDE, ZINC OXIDE | Kenvue Brands LLC | 003123d2-9675-fdd2-e063-6294a90a0130 | 2025-07-28 | Warnings | 15FIX9V2JP |
| Neutrogena Mineral Ultra Sheer Face SPF 70 | TITANIUM DIOXIDE, ZINC OXIDE | Kenvue Brands LLC | 20e0badf-fe25-1d27-e063-6294a90a7cfe | 2025-07-28 | Warnings | 15FIX9V2JP |
| Dolce and Gabbana Everlast Foundation SPF 20 01N Light | OCTISALATE, OCTOCRYLENE, TITANIUM DIOXIDE, ZINC OXIDE | Dolce & Gabbana Beauty S.R.L | 2ccf4e45-4cec-417d-9f4c-28f376025f1d | 2025-07-25 | Warnings | 15FIX9V2JP |
| Lisinopril and Hydrochlorothiazide | LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS | Solco Healthcare LLC | 96922ddc-e87f-4670-b22e-0ffd0d8f66e1 | 2025-07-25 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Sunscreen | TITANIUM DIOXIDE 6.8% | Baxter of California, LLC | 146030bc-2bf4-25ea-e063-6294a90a4613 | 2025-07-24 | Warnings | 15FIX9V2JP |
| Spironolactone and Hydrochlorothiazide | SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE | Mylan Institutional Inc. | f2a4fbc0-650b-440d-9555-c1720fe0fe35 | 2025-07-22 | Warnings, Adverse reactions | 0J48LPH2TH |
| La Defense Broad Spectrum SPF 30 Mineral Sunscreen | ZINC OXIDE, TITANIUM DIOXIDE | Luzern Laboratories, Inc | 3f00befa-415d-415d-89e1-6ba8770ba51e | 2025-07-21 | Warnings | 15FIX9V2JP |
| Losartan potassium and Hydrochlorothiazide | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | Macleods Pharmaceuticals Limited | a04b5622-2c49-4d61-92b1-5dc523af7a24 | 2025-07-21 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Amarte ULTRA VEIL Daily | SUNSCREEN | Amarte USA LLC | 39e9ca98-d0e8-6b8f-e063-6394a90aa366 | 2025-07-15 | Warnings | 15FIX9V2JP |
| Amarte ULTRA VEIL BB Fair | SUNSCREEN | Amarte USA LLC | 39e87950-4103-c2eb-e063-6394a90a0552 | 2025-07-15 | Warnings | 15FIX9V2JP |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.